106116-42-1

Basic information

• Product Name: 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE
• Synonyms: 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE
• CAS NO: 106116-42-1
• Molecular Formula: C₉H₁₁BrO
• Molecular Weight: 215.09
• Mol File: 106116-42-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE(106116-42-1)
• EPA Substance Registry System: 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE(106116-42-1)

Safety Data

• Hazardous Substances Data: 106116-42-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE is used as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, facilitating the synthesis of a wide range of compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE is utilized as a starting material for the development of new drugs. Its specific functional groups and structural features make it a valuable component in the design and synthesis of pharmaceutically active molecules.
Used in Material Science:
Due to its potential applications in material development, 1-(BROMOMETHYL)-3-METHOXY-5-METHYLBENZENE is explored in material science for the creation of new materials with specific properties, such as improved stability or reactivity.
Safety Note:
It is crucial to handle 1-(bromomethyl)-3-methoxy-5-methylbenzene with caution as it is a potentially hazardous chemical. Its use should be restricted to trained professionals operating within a controlled laboratory environment to ensure safety and proper disposal or management of the compound.

Upstream product

• 874-63-5 3,5-dimethylmethoxybenzene 
• 34241-39-9 azobisisobutyronitrile 

Downstream Products

• 200214-25-1 2-(3-methoxy-5-methylphenyl)acetonitrile 
• 90674-26-3 3-methoxy-5-methyl-benzaldehyde 
• 798566-26-4 6,7-dimethoxy-1-(3-methoxy-5-methyl-benzyl)-3,4-dihydro-isoquinoline-4-carboxylic acid ethyl ester 
• 798566-27-5 6,7-dimethoxy-1-(3-methoxy-5-methyl-benzyl)-isoquinoline-4-carboxylic acid ethyl ester 
• 798566-25-3 2-(3,4-dimethoxy-phenyl)-3-[2-(3-methoxy-5-methyl-phenyl)-acetylamino]-propionic acid ethyl ester 

Relevant articles and documents

Reactions of [2-(2-Naphthyl)phenyl]acetylenes and 2-(2-Naphthyl)benzaldehyde O-Phenyloximes: Synthesis of the Angucycline Tetrangulol and 1,10,12-Trimethoxy-8-methylbenzo[c]phenanthridine

The Suzuki–Miyaura coupling reaction between (1,4,5-trimethoxynaphthalen-2-yl)boronic acid and 2-iodo-3-methoxy-5-methylbenzaldehyde gave the intermediate 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-yl)benzaldehyde. Conversion of this benzaldehyde

Synthesis of a landomycinone skeleton via Masamune-Bergmann cyclization

In this report, a synthetic study of landomycinone via Masamune-Bergmann cyclization is described. A 10-membered 1,2-dialkynylbenzene derivative was designated as a key intermediate in the formation of an angular tetracyclic core via Masamune-Bergmann cyclization. Cyclization was expected to proceed under mild heating conditions based on a DFT transition state analysis of the 10-membered enediyne. The enediyne was successfully prepared by intramolecular NHK cyclization in good yield and underwent Masamune-Bergman cyclization at 70 °C for 2 h. However, an undesired β-elimination of the secondary alcohol was involved in the cyclization. In addition, iodination at the 12 position did not occur due to the steric hindrance of two methyl groups. This methodology should be widely applicable to the synthesis of various types of highly oxy-functionalized anthraquinone derivatives as well as landomycinone, and should be a useful way to clarify structure-activity relationships. the Partner Organisations 2014.

Roles of the synergistic reductive O-methyltransferase GilM and of O-methyltransferase GilMT in the gilvocarcin biosynthetic pathway

Two enzymes of the gilvocarcin biosynthetic pathway, GilMT and GilM, with unclear functions were investigated by in vitro studies using purified, recombinant enzymes along with synthetically prepared intermediates. The studies revealed GilMT as a typical

Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that interfere with the replication of human immunodeficiency virus (HIV) are being pursued with guidance from molecular modeling including free-energy perturbation (FEP) calculations for protein-in

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I) where in R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

The first total synthesis of (±)-γ-herbertenol, a herbertene isolated from a non-herbertus source

The structure of the aromatic sesquiterpene, (±)-γ- herbertenol, the first herbertane to be isolated from a non-herbertus source, was confirmed by a total synthesis, employing a Claisen rearrangement and ring-closing metathesis. Georg Thieme Verlag Stuttg

GFAT INHIBITORS

Compounds of formula (I) are provided as well as pharmaceutically acceptable salts and esters thereof, wherein the substituents are as disclosed in the specification. The compounds have utility for the treatment of type 2 diabetes mellitus.

AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS

There is provided compounds of formula I, wherein R 1, R 2, R 3, R x, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required as in thrombosis or as anticoagulants.

N-(4- carbamimidoyl-phenyl) -glycine derivatives

The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

An intramolecular arylation route to the kinafluorenones

Intramolecular palladium-mediated arylation approaches to benzo[b]fluorenes have been investigated. The methodology has been applied in a short synthesis of kinafluorenone 2, providing an effective alternative to Friedel-Crafts-based approaches. (C) 2000 Elsevier Science Ltd.